You may send us your comments on this form by clicking the button below. You will first be asked to supply your name, email address, and location. You must then acknowledge our data protection ...
The idea is huge, and the benefits are big for burn patients. Spray on skin, called RECELL, is now approved for both adults and children, sparing them the unnecessary pain of dozens of skin grafts. UC ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The expanded approval of Recell includes full-thickness ...
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound ...
VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted ...
The U.S. FDA granted premarket approval to Avita Medical Inc.’s Recell system for a wide range of full-thickness skin defects, potentially quintupling the company’s market opportunity. Recell is a ...
VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and ...
Please provide your email address to receive an email when new articles are posted on . The RECELL system was successful in repigmenting skin in patients with vitiligo, Avita Medical announced in a ...
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a ...
Avita Medical, a British company in the process of moving to the L.A. area, believes it has the next big thing in regenerative skin care: genetically personalized spray that can more completely heal ...
Regenerative medicine company Avita Medical Inc. raised AU$23 million (US$15 million) through a private placement on the Australian Securities Exchange (ASX:AVH) to support growth of its Recell ...
The External Assessment Centre excluded all the studies identified by the sponsor because they were outside the scope of the evaluation, although it did recognise that the studies contained useful ...